Cyclosporine versus tacrolimus: cost-effectiveness analysis for renal transplantation in Brazil

OBJECTIVE To analyze the cost-effectiveness of treatment regimens with cyclosporine or tacrolimus, five years after renal transplantation.METHODS This cost-effectiveness analysis was based on historical cohort data obtained between 2000 and 2004 and involved 2,022 patients treated with cyclosporine or tacrolimus, matched 1:1 for gender, age, and type and year of transplantation. Graft survival and the direct costs of medical care obtained from the National Health System (SUS) databases were used as outcome results.RESULTS Most of the patients were women, with a mean age of 36.6 years. The most frequent diagnosis of chronic renal failure was glomerulonephritis/nephritis (27.7%). In five years, the tacrolimus group had an average life expectancy gain of 3.96 years at an annual cost of R$78,360.57 compared with the cyclosporine group with a gain of 4.05 years and an annual cost of R$61,350.44.CONCLUSIONS After matching, the study indicated better survival of patients treated with regimens using tacrolimus. However, regimens containing cyclosporine were more cost-effective.

Schistosoma mansoni: acquired immunity in mice after the use of oxamniquine at the evolutive skin and pulmonary phases

Mice infected with 350 cercariae of Schistosoma mansoni (LE strain) were treated with oxamniquine, at the dose of 400 mg/kg, 24, 48, 72, and 96 h after infection. Forty days after the treatment, the animals were submitted to a challenge infection with 80 cercariae, through the abdominal and ear skins. The number of immature worms in the animal groups treated 24 and 96 h after the first infection was found to be lower than that in the control group, thus showing that the death of schisto-somes by chemotherapy, at the skin and pulmonary phases, causes an acquired resistance state.

Anti-HCV related to HCV PCR and risk factors analysis in a blood donor population of Central Brazil

Data concerning HCV infection in Central Brazil are rare. Upon testing 2,350 voluntary blood donors from this region, we found anti-HCV prevalence rates of 2.2% by a second generation ELISA and 1.4% after confirmation by a line immunoassay. Antibodies against core, NS4, and NS5 antigens of HCV were detected in 81.8%, 72.7%, and 57.5%, respectively, of the positive samples in the line immunoassay. HCV viremia was present in 76.6% of the anti-HCV-positive blood donors. A relation was observed between PCR positivity and serum reactivity in recognizing different HCV antigens in the line immunoassay. The majority of the positive donors had history of previous parenteral exposure. While the combination of ALT>50 IU/l and anti-HBc positivity do not appear to be good surrogate markers for HCV infection, the use of both ALT anti-HCV tests is indicated in the screening of Brazilian blood donors.

Toxoplasma encephalitis in AIDS patients in São Paulo during 1988 and 1991. A comparative retrospective analysis

We conducted a retrospective analysis of Toxoplasma encephalitis patients from Instituto de Infectologia Emílio Ribas, the main AIDS hospital of São Paulo, Brazil, during two different stages of the HIV epidemics, in 1988 (38 patients) and 1991 (33 patients). There were AIDS-related demographic differences, but the clinical presentation and diagnostic efficiency were similar, usually based on tomography and clinical response to therapy, with a clear distinction from other CNS infections, based on clinical and laboratory findings. Specific serologic studies were performed less often in 1991, with a high frequency of therapy change. The direct acute death rate from Toxoplasma encephalitis was high during both periods, i.e. 8/38 in 1988 and 10/33 in 1991. The direct acute death rate for the patients from the two periods as a whole was 25.4% (18/71), related to the time of HIV infection, absence of fever and presence of meningeal irritation at presentation, blood leukocytes higher than 10,000/mm³ and blood lymphocytes lower than 350/mm³. Toxoplasma encephalitis is a preventable disease when adequate prophylactic therapy is used and is relatively easy to treat in diagnosed HIV patients. Unfortunately, this severe and deadly disorder is the HIV diagnostic disease in several patients, and our data support the need for careful management of these patients, especially in those countries with a high toxoplasmosis prevalence where AIDS is concurrent with economic and public health problems.

Clinical laboratory assessment of hepatitis C and HIV coinfected patients according to the antiretroviral therapy received

During the year of 2001, a retrospective, descriptive study in order to determine the influence of the antiretroviral therapy received by 111 HIV-HCV coinfected patients who had undergone at least one liver biopsy was conduced, 74 of them were treated with a protease inhibitor regimen (WPI), and 37 with a non-protease inhibitor regimen (NPI). The main characteristics found were: a young patient population (mean age 41 years old in both groups), composed in most part of male individuals (74.3% WPI and 51.4% NPI) with previous risk factors for both infections (WPI 93.2% and NPI 89.2%). The most significant findings included AIDS-defining disease (WPI 18.9% and NPI 13.5% of the cases), elevated hepatic enzyme levels (WPI: SGOT 52.1 and NPI 53.2), absence of liver disease-related symptoms (16.2% for both groups), average CD4 count > 350 for both groups (WPI 362.2 and NPI 378.1), predominantly low-grade fibrosis in both populations (0-2 in 63.6% of WPI patients and in 80% of NPI patients), with necro-inflammatory activity ranging from 5-7 in 51.3% and 42.9% of WPI patients and NPI patients, respectively. It is suggested a sequential biopsy to better evaluate the evolution of the hepatic disease, according to the HAART regimen received.

Scientific authorships and collaboration network analysis on Chagas disease: papers indexed in PubMed (1940-2009)

Chagas disease is a chronic, tropical, parasitic disease, endemic throughout Latin America. The large-scale migration of populations has increased the geographic distribution of the disease and cases have been observed in many other countries around the world. To strengthen the critical mass of knowledge generated in different countries, it is essential to promote cooperative and translational research initiatives. We analyzed authorship of scientific documents on Chagas disease indexed in the Medline database from 1940 to 2009. Bibliometrics was used to analyze the evolution of collaboration patterns. A Social Network Analysis was carried out to identify the main research groups in the area by applying clustering methods. We then analyzed 13,989 papers produced by 21,350 authors. Collaboration among authors dramatically increased over the study period, reaching an average of 6.2 authors per paper in the last five-year period. Applying a threshold of collaboration of five or more papers signed in co-authorship, we identified 148 consolidated research groups made up of 1,750 authors. The Chagas disease network identified constitutes a "small world," characterized by a high degree of clustering and a notably high number of Brazilian researchers.

HISTOPLASMIN SURVEY IN HIV-POSITIVE PATIENTS: RESULTS FROM AN ENDEMIC AREA IN NORTHEASTERN BRAZIL

SUMMARY Background. Disseminated histoplasmosis is common in AIDS patients with advanced immunosuppression in Ceará, Northeastern Brazil. The goal of this study was to determine the prevalence of Histoplasma infection in patients with HIV/AIDS living in Fortaleza, the capital of Ceará. Methods. Intradermal tests with histoplasmin (mycelial phase) were performed in 161 HIV patients with CD4 ≥ 350 cells/mm 3 . Evidence of recent illness was evaluated with immunodiffusion (ID) tests in 76 of these individuals. Results. A total of 11.8% of patients reacted to histoplasmin and 2.63% had ID test positive to Histoplasma. The presence of mango trees (Mangifera indica) in the patient neighborhood (OR = 2.870; 95% CI = 1.081-7.617; p = 0.040) and past activity involving soil (OR = 2.834; 95% CI = 1.045-7.687; p = 0.045) or visits to a farm (OR = 3.869; 95% CI = 1.189-12.591; p = 0.033) were significantly associated with Histoplasma infection. Conclusions. Patients with HIV living in Fortaleza have an expressive prevalence of infection with Histoplasma.

PREVALENCE, RISK FACTORS AND SYMPTOMS ASSOCIATED TO INTESTINAL PARASITE INFECTIONS AMONG PATIENTS WITH GASTROINTESTINAL DISORDERS IN NAHAVAND, WESTERN IRAN

We studied the prevalence of intestinal parasites (IPs), their risk factors and associated symptoms among patients with gastrointestinal disorders. A total of 1,301 participants aged 22 days-90 years were enrolled in this study. We used a structured questionnaire to obtain socio-demographic and stool examination to investigate intestinal parasite infections. Data analysis was performed using SPSS16. The overall prevalence of intestinal parasites (IPs) was 32.2% (419/1,301). Three hundred and fifty nine cases/1,301 (27.6%) were infected with a single parasite and 60/1,301 cases (4.6%) presented polyparasitism. The most common IP was Blastocystis sp. 350/1,301 (26.9%), followed by Entamoeba coli 38/1,301 (2.92%), Giardia lamblia 30/1,301 (2.3%) and Cryptosporidium spp. 17/1,301 (1.3%). Regarding the socio-demographic variables, educational status (p = 0.001), contact with domestic animals and soil (p = 0.02), age above 15 years (p = 0.001) and seasons (p = 0.001) were significantly associated to intestinal parasitic infections. Concerning clinical characteristics, the presence of IPs was significantly associated to diarrhea (OR = 1.57; CI 95% = 1.24-1.98; p < 0.001) and dysentery (OR = 1.94; CI 95% = 1.03-3.66; p < 0.04). Our findings suggest that IPs are one of the main causal agents of gastrointestinal disorders. Improving the knowledge on local risk factors such as poverty, low level of education, poor sanitation, contact with soil and contact with domestic animal is warranted.

Ensaios terapêuticos no tracoma visando a campanha de tratamento em massa

Uma nova sulfamida de eliminação prolongada, o Ro 4-4393, foi ensaiada na terapêutica do trciccrna, em 350 escolares de zona endêmica, em comparação ao uso tópico de antibióticos. Diversos esquemas de administração foram adotados, desde 20 mg/kg até 50 mg/kg, a intervalos semanais, quinzenais, mensais e em dose única. Os resultados obtidos com a maioria dos esquemas foram equiparáveis àqueles proporcionados pelo uso local de antibióticos. O tempo de controle é ainda insuficiente para conclusões definitivas, e sugere-se o estudo de novos esquemas posclógicos com o Ro 4-4393.

Prevalência sorológica da doença de chagas e correlação sorológico-eletrocardiográfica em populações não selecionadas do município de Encruzilhada do sul, Rio Grande do Sul

No mês de julho de 1974, no plano de estudo da endemia chagásica na Zona Sul do Rio Grande do Sul, foram colhidas 360 amostras de sangue e registrado igual número de eletrocardiogramas entre as populações rurais de 10 localidades do Município de Encruzilhada do Sul (R. G. do Sul). Dez amostras não puderam ser utilizadas por material insuficiente, anticomplementaridade etc. Das 350 submetidas à fixação de complemento, 104 reagiram positivamente para a Doença de Chagas (29,71%). Dos 350 eletrocardiogramas analisados, 116 apresentaram alterações de vários tipos (33,14%), sendo que 41 pertencem aos 104 indivíduos com sorologia positiva (39,42%) e 75 aos 246 indivíduos com sorologia negativa (30,46%) A diferença percentual de 8,94% entre os dois grupos não se mostrou estatisticamente significativa, Portanto a positividade sorológica parece não ser fator condicionante de um maior índice de alterações eletrocardiográficas, a exemplo do que acontece em outras zonas endêmicas. O Autor compara os resultados atuais com aqueles obtidos em 1954 por Brant e Cols. no mesmo Município, para concluir que neste intervalo de tempo houve um substancial aumento na prevalência sorológica e nas alterações eletrocardiográficas, sem que contudo se delineasse um maior índice de alterações nos indivíduos com positividade sorológica.

Estudo radiológico longitudinal do esôfago, em área endêmica de doença de Chagas, em um período de 13 anos

Foi realizado estudo radio lógico longitudinal do esôfago abrangendo um período de 13,2 anos, na população do município de Mambaí no estado de Goiás. Os exames foram realizados na sede municipal, com aparelho de abreugrafia, usando filme de 70 milímetros. Foram examinados 731 indivíduos dos quais 382 (52,3%) eram soropositivos. Em relação ao sexo 350 (47,9%) eram do sexo masculino e 381 (52, 1%) do sexo feminino. A incidência de megaesôfago na população estudada foi 7,9% e entre os soropositivos 14,2 %. A progressão da esofagopatia entre os soropositivos do sexo masculino foi 21,7% e no sexo feminino 16,6%.

Diagnóstico e tratamento da hepatite B

A hepatite B constitui grave problema de saúde pública. Estima-se que 350 milhões de pessoas, ou seja, 5% da população mundial sejam portadores dessa virose. Admite-se que a infecção evolui para a cura em 90% a 95% dos casos e para o estado de portador crônico nos restantes 5% a 10%; a infecção persistente pode resultar também em cirrose, insuficiência hepática e carcinoma hepatocelular. O diagnóstico de qualquer das formas clínicas da hepatite B realiza-se através de técnicas sorológicas. Os médicos, hoje, possuem acesso a modernas técnicas laboratoriais capazes de avaliar a carga viral, o índice de replicação do agente infeccioso e a eficácia das novas medicações utilizadas. Vários agentes antivirais têm sido usados no tratamento dos indivíduos com hepatite crônica, como o intérferon alfa, a lamivudina, o famciclovir, e o adefovir dipivoxil, entre outros. A imunização ativa utilizando as modernas vacinas recombinantes constitui, na atualidade, a arma mais importante no combate à infecção pelo vírus da hepatite B.

Neurocisticercose

Estima-se que 50 milhões de indivíduos estejam infectados pelo complexo teníase/cisticercose no mundo e que 50.000 morrem a cada ano. Cerca de 350.000 pessoas encontram-se infectadas na América Latina. Em Ribeirão Preto, no Brasil, diagnosticou-se a neurocisticercose em 7,5% dos pacientes admitidos em enfermaria de neurologia. As manifestações clínicas incluem crises epilépticas, hipertensão intracraniana, meningite cisticercótica, distúrbios psíquicos, forma apoplética ou endarterítica e síndrome medular. A gravidade da doença pode ser ajuizada pela sua letalidade que varia de 16,4% a 25,9%. O diagnóstico de neurocisticercose baseia-se na análise dos exames de neuroimagem (tomografia computadorizada e ressonância nuclear magnética) e no exame do líquido cefalorraquiano. Recomenda-se, atualmente, o albendazol como o medicamento de primeira escolha no tratamento da doença, geralmente em associação com corticoesteróides. Os autores defendem a notificação compulsória e medidas preventivas no controle da parasitose. No Brasil, na ausência de programa nacional de controle, os projetos de prevenção constituem iniciativas regionais, tendo como lema o alerta da OMS: "Pense globalmente, atue localmente".

Hepatite D

O vírus da hepatite D (VHD), também chamado de vírus delta, é um pequeno vírus contendo RNA circular. O VHD causa infecção, quando há coinfecção com o vírus da hepatite B (VHB) em indivíduos normais ou superinfecção em portadores crônicos do VHB. Três genótipos já foram clonados e seqüenciados. A infecção apresenta distribuição mundial, sendo a região ocidental da Amazônia brasileira considerada área de alta endemicidade. Estima-se que 18 milhões de pessoas encontram-se infectadas pelo vírus entre os 350 milhões de portadores crônicos do VHB no mundo. As vias de transmissão do VHD e os fatores de risco mostram-se similares aos da infecção pelo VHB. O diagnóstico se faz pela identificação imuno-histológica do HDAg no fígado e pelo encontro das frações IgM e IgG anti-HD no soro por radioimunoensaio ou ELISA. O curso clínico da infecção pelo VHD mostra-se variável. Os pacientes podem apresentar formas fulminantes de hepatite. As formas crônicas associam-se a achados histopatológicos graves no fígado, com curso rápido e progressivo, evoluindo para cirrose, insuficiência hepática e morte. O interferon alfa constitui a única opção terapêutica com algum efeito benéfico no tratamento da hepatite. O transplante hepático encontra indicação nos casos terminais de cirrose. A profilaxia indireta da infecção pelo VHD tornou-se possível com o advento da vacina contra o vírus da hepatite B.

História natural da hepatite crônica B

Estima-se que existam 350 milhões de portadores crônicos do VHB distribuídos ao redor do mundo. Três fases de infecção crônica pelo VHB são reconhecidas: fase de imunotolerância (HBsAg e HBeAg positivos, altos títulos de HBV-DNA, ALT normal e não evidência de doença hepática ativa); fase imunoativa ou de hepatite crônica B (HBsAg e HBeAg positivos, altos títulos de HBV-DNA, ALT elevada e evidência de doença hepática ativa); fase de portador inativo do VHB ou assintomático (HBsAg no soro sem o HBeAg , títulos do HBV-DNA < 10(5) cópias p/ml, ALT normal). Hepatite crônica B é dividida em duas formas maiores: doença HBeAg positiva (VHB tipo selvagem); doença HBeAg negativa (pré-core, core promoter VHB variante). As duas formas podem evoluir para cirrose hepática, descompensação hepática e câncer hepático. A proposta deste artigo foi o de rever os principais aspectos da história natural da hepatite crônica B.